Fusion Antibodies PLC
LSE:FAB
Intrinsic Value
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. [ Read More ]
The intrinsic value of one
FAB
stock under the Base Case scenario is
23.72
GBX.
Compared to the current market price of 5.5 GBX,
Fusion Antibodies PLC
is
Undervalued by 77%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Fusion Antibodies PLC's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Fusion Antibodies PLC
| Current Assets | 3.2m |
| Cash & Short-Term Investments | 1.2m |
| Receivables | 1.5m |
| Other Current Assets | 552k |
| Non-Current Assets | 743k |
| PP&E | 743k |
| Current Liabilities | 1.1m |
| Accounts Payable | 1.1m |
| Other Current Liabilities | 83k |
| Non-Current Liabilities | 270k |
| Long-Term Debt | 250k |
| Other Non-Current Liabilities | 20k |
FAB Profitability Score
Profitability Due Diligence
Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
FAB Solvency Score
Solvency Due Diligence
Fusion Antibodies PLC's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Fusion Antibodies PLC's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FAB Price Targets Summary
Fusion Antibodies PLC
Shareholder Return
FAB Price
Fusion Antibodies PLC
| Average Annual Return | 17% |
| Standard Deviation of Annual Returns | 39.94% |
| Max Drawdown | -98% |
| Market Capitalization | 3.3m GBX |
| Shares Outstanding | 59 453 700 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Fusion Antibodies PLC
Country
Industry
Market Cap
Dividend Yield
Description
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
Contact
IPO
Employees
Officers
The intrinsic value of one
FAB
stock under the Base Case scenario is
23.72
GBX.
Compared to the current market price of 5.5 GBX,
Fusion Antibodies PLC
is
Undervalued by 77%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
